Use of Inotropic Agents in Treatment of XXXX .

@entity1 @entity712 @entity452 @entity998 @entity935 @entity6838 @entity6759 @entity881 @entity7604 @entity1063
The most common use of inotropes is among hospitalized @entity1 with acute decompensated @entity712 , with reduced left ventricular ejection fraction and with signs of @entity881 in the setting of a @entity998 . Inotropes can be used in @entity1 with severe systolic @entity712 awaiting heart transplant to maintain hemodynamic stability or as a bridge to decision. In cases where @entity1 are unable to be weaned off inotropes, these agents can be used until a definite or escalated supportive therapy is planned, which can include coronary revascularization or mechanical circulatory support (intra-aortic balloon pump, extracorporeal membrane oxygenation, impella, left ventricular assist device, etc.). Use of inotropic drugs is associated with risks and adverse events. This review will discuss the use of the inotropes @entity6838 , @entity935 , @entity452 , @entity1063 , @entity7604 , @entity6759 , and omecamtiv mecarbil. Long-term inotropic therapy should be offered in selected @entity1 . A detailed conversation with the @entity1 and family shall be held, including a discussion on the risks and benefits of use of inotropes. @entity712 @entity1 awaiting heart transplants are candidates for intravenous inotropic support until the donor heart becomes available. This helps to maintain hemodynamic stability and keep the fluid status and pulmonary pressures optimized prior to the surgery. On the other hand, in @entity1 with severe @entity712 who are not candidates for advanced @entity712 therapies, such as transplant and mechanical circulatory support, inotropic agents can be used for palliative therapy. Inotropes can help reduce frequency of hospitalizations and improve symptoms in these @entity1 .
